Development of neuroactive steroids for the treatment of postpartum depression.

77 Remission (HAMD‐17 total score ≤ 7) was observed in 7 of 10 patients in the brexanolone group compared to 1 of 11 patients in the placebo group at 60 hours ( P = .0364), whereas response rates (50% or greater reduction from baseline in total HAMD‐17 score) did not reach statistical significance between groups (7 in 10 patients in the brexanolone group compared to 4 of 11 patients in the placebo group; P = .1450). 77 There were no serious adverse events (AEs) or discontinuations in either group, and the most frequent AEs in the brexanolone group were dizziness (2 patients in the brexan

also in 111,027 other papers